Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
Groenendijk FH, Mellema WW, van der Burg E, Schut E, Hauptmann M, Horlings HM, Willems SM, van den Heuvel MM, Jonkers J, Smit EF, Bernards R. Groenendijk FH, et al. Among authors: schut e. Int J Cancer. 2015 Mar 15;136(6):1434-44. doi: 10.1002/ijc.29113. Epub 2014 Aug 8. Int J Cancer. 2015. PMID: 25080865 Free PMC article. Clinical Trial.
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J. Evers B, et al. Among authors: schut e. Clin Cancer Res. 2008 Jun 15;14(12):3916-25. doi: 10.1158/1078-0432.CCR-07-4953. Clin Cancer Res. 2008. PMID: 18559613 Free article.
PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma.
Boelens MC, Nethe M, Klarenbeek S, de Ruiter JR, Schut E, Bonzanni N, Zeeman AL, Wientjens E, van der Burg E, Wessels L, van Amerongen R, Jonkers J. Boelens MC, et al. Among authors: schut e. Cell Rep. 2016 Aug 23;16(8):2087-2101. doi: 10.1016/j.celrep.2016.07.059. Epub 2016 Aug 11. Cell Rep. 2016. PMID: 27524621 Free PMC article.
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR, Jonkers J. Drost R, et al. Among authors: schut e. Cancer Cell. 2011 Dec 13;20(6):797-809. doi: 10.1016/j.ccr.2011.11.014. Cancer Cell. 2011. PMID: 22172724 Free article.
Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.
Kas SM, de Ruiter JR, Schipper K, Schut E, Bombardelli L, Wientjens E, Drenth AP, de Korte-Grimmerink R, Mahakena S, Phillips C, Smith PD, Klarenbeek S, van de Wetering K, Berns A, Wessels LFA, Jonkers J. Kas SM, et al. Among authors: schut e. Cancer Res. 2018 Oct 1;78(19):5668-5679. doi: 10.1158/0008-5472.CAN-18-0757. Epub 2018 Aug 16. Cancer Res. 2018. PMID: 30115694
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Zingg D, et al. Among authors: schut e. Nature. 2022 Aug;608(7923):609-617. doi: 10.1038/s41586-022-05066-5. Epub 2022 Aug 10. Nature. 2022. PMID: 35948633 Free PMC article. Clinical Trial.
51 results